Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

348276

registered interest
date	03/06/2015
answering body	Department for Energy and Climate Change
answering dept id	63
answering dept short name	Energy and Climate Change
answering dept sort name	Energy and Climate Change
hansard heading	Wind Power
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Energy and Climate Change, if she will take steps to reduce the subsidies available to the promotion and construction of on-shore wind farms; and if she will bring forward proposals to ensure that local planning controls over such projects involve adequate consultation with local residents before consent is granted.
tabling member constituency	North Thanet
tabling member printed	Sir Roger Gale
uin	954
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>We are driving forward plans to deliver our manifesto pledge to end new subsidies for onshore wind and to give local communities the final say on windfarm applications as soon as possible. We will publish our plans and timetable for these changes shortly.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 08/06/2015 09:58:46 answering member 4117 label Biography information for Andrea Leadsom
tabling member	87 label Biography information for Sir Roger Gale

348397

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	962
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 963 964 965 question first answered 08/06/2015 10:53:58 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348398

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate his Department has made of the number of people with hidradenitis suppurativa in the UK; how much his Department has spent on research into hidradenitis suppurativa in the last four years; and what guidance his Department gives on support to be given through the NHS for people with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	963
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 964 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348399

registered interest
date	03/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hidradenitis Suppurativa: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the care pathways for patients with hidradenitis suppurativa.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	964
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p>Hidradenitis suppurativa (HS) affects around 90,000 people in England. The Department’s National Institute for Health Research Clinical Research Network (CRN) is providing research infrastructure to enable molecular genetic analysis of HS, although expenditure on this cannot be disaggregated from total CRN spend.</p><p> </p><p><br> Information on the diagnosis, treatment care and support of patients with HS can be found on the NHS Choices website. This also provides links to the British Association of Dermatologists, which has produced a patient information leaflet on HS, and the HS Trust, which is the United Kingdom‘s leading charity for the condition. More information can be found at the following link:</p><p> </p><p><br> <a href="http://www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx" target="_blank">www.nhs.uk/conditions/hidradenitis-suppurativa/Pages/Introduction.aspx</a></p><p> </p><p><br> In terms of the care pathway for the condition, HS can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin, which a general practitioner may prescribe. For those patients with the most serious forms of HS who cannot be managed through routine access to treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with the involvement of a range of health and care professionals, subject to a patient’s needs. More information can be found at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 962 963 965 question first answered 08/06/2015 10:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

348415

registered interest
date	03/06/2015
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Employment and Support Allowance: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, whether it is his policy that the proposed legislation requiring young people to earn or learn will extend to existing claimants of employment and support allowance under the age of 21.
tabling member constituency	Birmingham, Northfield
tabling member printed	Richard Burden
uin	1030
answer	answer is ministerial correction date of answer 08/06/2015 answer text <p /> <p>We will set out our policy design in due course.</p> answering member constituency Witham answering member printed Priti Patel question first answered 08/06/2015 10:07:06 answering member 4066 label Biography information for Priti Patel
tabling member	301 label Biography information for Richard Burden